ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

prabotulinumtoxin A

Also written as “ABP-450”, “PrabotulinumtoxinA-Xvfs” and “DWP450”.

Its studies are mostly in Migraine Disorders · Torticollis, led by 3 companies.

Drug pagePrabotulinumtoxin A: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 28, 20219 company-led studies, 1 open or runningNext primary completion: May 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AEON Biopharmaits history only40 open or runningphase 2since Mar 28, 2021Mar 28, 2021none ahead
Daewoong Pharmaceutical31 open or runningphase 3since Mar 2, 2020Mar 2, 2020May 2028phase 3 · NCT07783763
Evolusits history only20 open or runningphase 2since Apr 21, 2015Apr 21, 2015none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP and ethica Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Daewoong Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2020First study: phase 3 study in Benign Masseteric HypertrophyFirst studyNCT04294251 · 180 enrolled · Korea, Republic of
  2. Apr 3, 2024Phase 3 study in Moderate to Severe Glabellar LinesNCT06354127 · 473 enrolled · China
  3. Aug 21, 2026Phase 3 study in Glabellar LinesNCT07783763 · 120 planned

Ahead

  1. May 2028Primary completion: phase 3 study in Glabellar LinesNCT07783763

TargetBeta

SNAP25 →read by rule
“Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme”ChEMBL 37, by rule

Other programs on SNAP25

ProgramCompanyFurthest phaseStudies
botulinum toxin type AAbbViephase 4286
trenibotulinumtoxinEruleAbbViephase 311

Studies

All 3 Daewoong Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07783763Glabellar Lines3Not yet recruitingMay 2028120
NCT06354127Moderate to Severe Glabellar Lines · China3CompletedNov 24, 2020473
NCT04294251Benign Masseteric Hypertrophy · Korea, Republic of3CompletedJan 7, 2021180

How it is read

Names in the registry

  • “ABP-450”, 4 entries
  • “PrabotulinumtoxinA-Xvfs”, 2 entries
  • “DWP450”, 2 entries
  • “DWP450 20 U”, 1 entry
  • “DWP-450 (Botulinum purified neurotoxin, Type A)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.